MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common shares
$3,497,825
Net cash provided by
financing activities
$3,355,419
Canceled cashflow
$142,406
Net change in cash
and cash...
$1,259,576
Canceled cashflow
$2,095,843
Payments for issuance
costs of common...
$142,406
Share-based compensation
$399,862
Accounts and other
receivable
-$217,387
Depreciation and
amortization
$25,460
Net cash used in
operating activities
-$2,087,334
Effect of exchange rate
changes on cash and cash...
-$8,509
Canceled cashflow
$642,709
Net loss
-$2,247,669
Accounts payable and
accrued liabilities
-$326,452
Prepaid expenses and
other current assets
$155,922
Back
Back
Cash Flow
source: myfinsight.com
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)